OraSure Technologies (NASDAQ:OSUR – Get Free Report) released its quarterly earnings results on Monday. The medical instruments supplier reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.05, FiscalAI reports. The firm had revenue of $30.91 million for the quarter, compared to analysts’ expectations of $31.00 million. OraSure Technologies had a negative return on equity of 19.09% and a negative net margin of 43.70%.
OraSure Technologies Stock Performance
OSUR traded up $0.09 during midday trading on Monday, hitting $3.53. The stock had a trading volume of 744,341 shares, compared to its average volume of 557,322. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.58. The business has a fifty day moving average of $3.73 and a 200 day moving average of $3.53. The company has a market cap of $243.46 million, a P/E ratio of -5.12 and a beta of 1.08.
Analyst Upgrades and Downgrades
A number of research firms have commented on OSUR. Craig Hallum raised shares of OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. Finally, Zacks Research raised shares of OraSure Technologies to a “hold” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.
About OraSure Technologies
OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.
Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.
Recommended Stories
- Five stocks we like better than OraSure Technologies
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
